The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TACTI-004: A double-blinded, randomized phase 3 trial in patients with advanced/metastatic non-small cell lung cancer receiving eftilagimod alfa (MHC class II agonist) in combination with pembrolizumab (P) and chemotherapy (C) versus placebo + P + C.
 
Giuseppe Lo Russo
Consulting or Advisory Role - Amgen (Inst); AstraZeneca/MedImmune; Bristol-Myers Squibb/Medarex; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Jhonson and Jhonson; Lilly; Merck Serono; MSD; Novartis; Pfizer; Pierre Fabre; REGENERON; Roche; Sanofi; Takeda
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb/Medarex (Inst); Celgene (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); MSD Oncology; MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BMS; MSD; Roche
 
Margarita Majem
Consulting or Advisory Role - AstraZeneca; BeiGene Beijing; Boehringer Ingelheim; Bristol-Myers Squibb; Helsinn Therapeutics; Janssen Oncology; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi; Takeda
Research Funding - AstraZeneca (Inst); BMS (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD Oncology; Pfizer; Roche
 
Kenneth O'Byrne
Stock and Other Ownership Interests - Carpe Vitae Pharmaceuticals; DGC diagnostics; RepLuca Pharmaceuticals
Honoraria - Amgen; Astrazeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; diacchi; Ipsen; Merck; Merck Sharp & Dohme; Pfizer/EMD Serono; Roche; Seagen; Takeda; TriStar Technology Group
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; diacchi; Ipsen; Merck Sharp & Dohme; Pfizer; Roche/Genentech; Sanofi; seagen
Speakers' Bureau - BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen-Cilag; Merck; Merck Sharp & Dohme; Pfizer; Roche; Seagen
Patents, Royalties, Other Intellectual Property - I am named on 4 active patents, 2 published and 2 provisional (Inst)
Travel, Accommodations, Expenses - Bayer Holding; Sanofi
 
Thorsten Goetze
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Foundation Medicine; Incyte; Lilly; MSD Oncology; Novartis; Roche; SERVIER
Speakers' Bureau - Lilly; MSD Oncology
Research Funding - AstraZeneca (Inst); Deutsche Forschungsgemeinschaft; Deutsche Krebshilfe (Inst); Gemeinsamer Bundesausschuss; Incyte (Inst); Lilly (Inst)
 
Christian Mueller
Employment - Immutep
Stock and Other Ownership Interests - Immutep
 
Frederic Triebel
Employment - Immutep
Leadership - Immutep
Stock and Other Ownership Interests - Immutep
Patents, Royalties, Other Intellectual Property - Being an inventor on patents on LAG-3 owned by Immutep SAS